DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
SGN-15 is an investigational drug.
There have been 72 clinical trials for SGN-15. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Hodgkin Disease. The leading clinical trial sponsors are Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., and Genentech, Inc.
There are two US patents protecting this investigational drug and thirteen international patents.
Recent Clinical Trials for SGN-15
|A Safety Study of SGN-TGT in Patients With Advanced Cancer||Seattle Genetics, Inc.||Phase 1|
|A Study of SGN-CD228A in Advanced Solid Tumors||Seattle Genetics, Inc.||Phase 1|
|A Safety Study of SGN-CD47M in Patients With Solid Tumors||Seattle Genetics, Inc.||Phase 1|
Top disease conditions for SGN-15
Top clinical trial sponsors for SGN-15
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGN-15||Start Trial||Compositions and methods for cancer immunotherapy||Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP)||Start Trial|
|SGN-15||Start Trial||Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents||Massachusetts Institute of Technology (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SGN-15||European Patent Office||1874342||2025-04-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|